ES2124250T3 - Anticuerpo especifico para un antigeno tumoral. - Google Patents

Anticuerpo especifico para un antigeno tumoral.

Info

Publication number
ES2124250T3
ES2124250T3 ES92850166T ES92850166T ES2124250T3 ES 2124250 T3 ES2124250 T3 ES 2124250T3 ES 92850166 T ES92850166 T ES 92850166T ES 92850166 T ES92850166 T ES 92850166T ES 2124250 T3 ES2124250 T3 ES 2124250T3
Authority
ES
Spain
Prior art keywords
antibody
specific antibody
tumor antigen
antigen
ecacc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92850166T
Other languages
English (en)
Spanish (es)
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2124250T3 publication Critical patent/ES2124250T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES92850166T 1991-07-03 1992-07-03 Anticuerpo especifico para un antigeno tumoral. Expired - Lifetime ES2124250T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
ES2124250T3 true ES2124250T3 (es) 1999-02-01

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92850166T Expired - Lifetime ES2124250T3 (es) 1991-07-03 1992-07-03 Anticuerpo especifico para un antigeno tumoral.

Country Status (19)

Country Link
US (1) US5552293A (enExample)
EP (1) EP0521842B1 (enExample)
JP (1) JP3194020B2 (enExample)
KR (1) KR100246681B1 (enExample)
AT (1) ATE171193T1 (enExample)
AU (2) AU658198B2 (enExample)
CA (1) CA2073124C (enExample)
DE (1) DE69226990T2 (enExample)
DK (1) DK0521842T3 (enExample)
EE (1) EE03031B1 (enExample)
ES (1) ES2124250T3 (enExample)
FI (1) FI109207B (enExample)
HU (2) HU218084B (enExample)
IE (1) IE80841B1 (enExample)
IL (1) IL102390A (enExample)
NO (1) NO315472B1 (enExample)
NZ (1) NZ243435A (enExample)
SE (1) SE9102074D0 (enExample)
WO (2) WO1993001302A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
ATE200679T1 (de) * 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
ES2619313T3 (es) * 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
WO2004004639A2 (en) * 2002-07-02 2004-01-15 Smithkline Beecham Corporation A novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3524611B1 (en) 2003-05-20 2020-12-30 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US9243062B2 (en) * 2005-08-11 2016-01-26 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
RU2595424C2 (ru) 2009-06-03 2016-08-27 Иммьюноджен, Инк. Способы конъюгации
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CN105209592A (zh) 2012-10-04 2015-12-30 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
WO2016081584A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
MX2018008383A (es) 2016-01-10 2019-05-30 Neotx Therapeutics Ltd Inmunoterapia contra el cáncer mediada por superantígeno mejorada por inmunopotenciador.
JP2019510741A (ja) 2016-02-05 2019-04-18 イミュノジェン・インコーポレーテッド 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
JP2022531978A (ja) 2019-05-15 2022-07-12 ネオティーエックス セラピューティクス リミテッド 癌治療
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
AU656906B2 (en) * 1990-07-20 1995-02-23 Active Biotech Ab Target specific antibody-superantigen conjugates and their preparation
AU657483B2 (en) * 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Also Published As

Publication number Publication date
HU211512A9 (en) 1995-11-28
FI935970A0 (fi) 1993-12-31
JPH05276987A (ja) 1993-10-26
IL102390A0 (en) 1993-01-14
HU218084B (hu) 2000-05-28
HUT71193A (en) 1995-11-28
WO1993001303A1 (en) 1993-01-21
AU658198B2 (en) 1995-04-06
EE03031B1 (et) 1997-08-15
NO934777D0 (no) 1993-12-22
AU2292092A (en) 1993-02-11
ATE171193T1 (de) 1998-10-15
DK0521842T3 (da) 1999-06-14
IE80841B1 (en) 1999-03-24
EP0521842A2 (en) 1993-01-07
WO1993001302A1 (en) 1993-01-21
JP3194020B2 (ja) 2001-07-30
FI109207B (fi) 2002-06-14
CA2073124C (en) 2007-06-19
EP0521842A3 (enExample) 1994-01-26
IE922188A1 (en) 1993-01-13
DE69226990D1 (de) 1998-10-22
US5552293A (en) 1996-09-03
HU9400011D0 (en) 1994-05-30
EP0521842B1 (en) 1998-09-16
AU1942592A (en) 1993-01-07
KR100246681B1 (ko) 2000-04-01
IL102390A (en) 1996-01-19
SE9102074D0 (sv) 1991-07-03
NO934777L (no) 1994-02-11
NO315472B1 (no) 2003-09-08
FI935970L (fi) 1993-12-31
DE69226990T2 (de) 1999-03-25
NZ243435A (en) 1994-10-26
CA2073124A1 (en) 1993-01-04

Similar Documents

Publication Publication Date Title
ES2124250T3 (es) Anticuerpo especifico para un antigeno tumoral.
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
DK517380A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
PT91201A (pt) Novos metodos para produzir anticorpos monoclonais aperfeicoados reactivos com a caquectina
DE3580654D1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
ATE94205T1 (de) Monoklonale antikoerper gegen melanoma-assoziierte antigene, hybridzellinien, die diese antikoerper produzieren, und ihre verwendung.
ATE41034T1 (de) Herstellung von protein a.
NO159887C (no) Monoklonalt antistoff.
DE69432951D1 (de) Regulierung der fruchtbarkeit mit transformierendem wachstumfaktor beta
DK517180A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
NO871573L (no) Fremgangsmaate for fremstilling av peptider.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
KR850001531A (ko) 인체 내부 백혈소-2(tcgf)와 인체면역글로부린의 빛 入연쇄에 대한 공통 구조를 인지하는 단일 영양 항체 및 단일 영양 항체를 생성하는 하이브리도마 세포계통
SU572590A1 (ru) Струйный усилитель
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
SU1459236A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus, используемый для получения моноклональных антител к listeria monocytogenes
IT7922928V0 (it) Impianto per la produzione di metano da liquami in genere e simili.
DK182188A (da) Humant tumorassocieret antigen
KR860001184A (ko) Pta-210 세포주를 이용한 인간성장 호르몬의 생산방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521842

Country of ref document: ES